サンプル依頼リスト カート
  • English
  • Korean
市場調査レポート
商品コード
1345368

慢性副鼻腔炎の世界市場-2023年～2030年

Global Chronic Rhinosinusitis Market - 2023-2030
出版日: | 発行: DataM Intelligence | ページ情報: 英文 186 Pages | 納期: 約2営業日

● お客様のご希望に応じて、既存データの加工や未掲載情報（例：国別セグメント）の追加などの対応が可能です。　 詳細はお問い合わせください。
価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=156.76円
慢性副鼻腔炎の世界市場-2023年～2030年
出版日: 2023年09月06日
発行: DataM Intelligence
ページ情報: 英文 186 Pages
納期: 約2営業日
ご注意事項 :
本レポートは最新情報反映のため適宜更新し、内容構成変更を行う場合があります。ご検討の際はお問い合わせください。
  • 全表示
  • 概要
  • 目次
概要

市場概要

慢性副鼻腔炎の世界市場は、2022年に26億米ドルに達し、2023-2030年の予測期間中にCAGR 7.3%で成長し、2030年には45億米ドルに達すると予測されます。

世界の慢性副鼻腔炎市場は、その動向に影響を与える様々な要因 (有病率の増加、より良い治療のための治験の増加など) によって、近年著しい成長を遂げています。より良い治療法の開発に対する政府の投資は、世界の慢性副鼻腔炎市場を引き続き牽引し、押し上げるでしょう。世界の産業界は、その影響を軽減するため、持続可能な実践にますます重点を置くようになっています。

さらに、慢性副鼻腔炎の治療法はありませんが、鼻腔灌流装置などの医療機器、ステロイド錠剤、抗生物質、生物製剤などの薬剤、鼻ステロイドスプレー、点鼻薬など、さまざまな種類の医療機器を使用することで病気を管理することができます。重症の場合は、関連症状をよりよく管理するために手術が考慮されます。ステロイド点鼻薬は、より良い管理のために最も一般的に使用されており、安全であると考えられています。

同様に、北米は慢性副鼻腔炎市場を独占しており、同地域の有利な償還政策、有病率の増加、高度で確立された医療インフラ、大手企業の存在により、最大の市場シェアを獲得しています。

慢性副鼻腔炎の有病率の増加、認知度の向上、治験の増加、新規治療薬に対する需要の増加、個別化医療の採用の増加、低侵襲処置に対する需要の増加、治療オプションの進歩が、予測期間にわたって世界の慢性副鼻腔炎市場を牽引すると予想される主な要因です。

市場力学

治験の増加が慢性副鼻腔炎市場の成長を牽引すると期待される

慢性副鼻腔炎関連の治験の増加は、予測期間にわたって市場を牽引すると期待されています。治験は主に、新薬、医療機器、その他の治療薬の安全性と有効性を知るために実施され、慢性副鼻腔炎の根本的なメカニズムに関する貴重な洞察も提供します。治験の肯定的な結果は、患者に新規治療薬の使用を促します。

例えば、2022年2月22日、神経および精神神経疾患を標的とした革新的な後期製品候補のポートフォリオを有する商業段階のバイオ医薬品会社であるBiohaven Pharmaceutical Holding Company Ltd.は、鼻ポリープの有無にかかわらず慢性副鼻腔炎（CRS）患者におけるNurtec ODT（リメゲパント）75mgの有効性と安全性を評価する第2/3相治験の登録を開始したと発表しました。

さらに、治験の良好な結果は、慢性副鼻腔炎の管理を改善・強化するために患者が利用できる治療の選択肢の幅を広げることで、新たな治療法の承認・導入につながる可能性もあります。治験はまた、より先進的な治療のための研究活動の機会を提供し、その結果、疾患の管理が改善され、患者の転帰が改善されます。

例えば、2022年9月8日、独自のXTreoプラットフォームを活用し、耳鼻咽喉（ENT）通路やその他の疾患組織への正確かつ持続的な局所的薬物送達を可能にする臨床段階の治療薬企業であるライラ・セラピューティクス社は、慢性副鼻腔炎（CRS）の成人患者を対象としたLYR-210の第3相ENLIGHTEN II治験における最初の患者の登録を発表しました。LYR-210は、治療にもかかわらず症状の残る数百万人のCRS患者のために、副鼻腔手術に代わるものとしてデザインされました。

慢性副鼻腔炎の認知度向上と関連治療が市場成長を牽引する見込み

慢性副鼻腔炎とその関連治療に対する認知度の向上が、予測期間中の市場を牽引すると予想されます。認知度の向上は、慢性副鼻腔炎の症状を早期に認識するのに役立ちます。これにより、迅速な診察、早期診断、より良い管理が可能になります。また、認知度の向上は、治療や患者の転帰改善にもつながります。

例えば、EUFOREAは2023年4月20日、ベルギーのブリュッセルで第2回「鼻ポリープを伴う慢性副鼻腔炎（CRSwNP）啓発デー」を開催すると発表しました。このキャンペーンの目的は、CRSwNPと併存疾患についての認識を高めること、あらゆるレベルの医療従事者に専門家によるケアを提供するよう促すこと、CRSwNPの症状について患者を教育することなどです。

さらに、慢性副鼻腔炎患者の多くは、自分の症状が他の要因によるものであるとして、自分がこの病気であることに気づいていない場合があります。このような啓発キャンペーンを通じて認知度を高めることで、自分の症状が医学的な症状を示している可能性があることを理解し、適切な診断と治療につなげることができます。認知度の向上は、新規治療オプションの需要も増加させます。

規制当局の承認の増加も慢性副鼻腔炎市場の成長を促進する見込み

慢性副鼻腔炎を管理するための新たな治療オプションの導入を可能にすることで、規制当局の承認の増加が予測期間中の市場の成長を促進します。これにより、患者にさらに強化されたより良い治療オプションを提供することができます。規制当局の承認は、慢性副鼻腔炎治療に関連するアンメットニーズに対処することで、革新的な治療オプションの開発を増加させます。

例えば、2023年5月4日、耳鼻咽喉（ENT）およびアレルギーの専門医が治療する患者に焦点を当てた製薬会社であるOptinose社は、米国食品医薬品局（FDA）が慢性副鼻腔炎の治療薬としてXHANCEの承認を求める新薬承認申請を受理したと発表しました。XHANCE（フルチカゾンプロピオン酸エステル）点鼻スプレーは、最も広く使用されている点鼻抗炎症薬と革新的なExhalation Delivery System（EDS）を組み合わせたドラッグデバイスコンビネーション製品です。

さらに、規制当局の承認により、承認された治療法がより多くの患者集団に利用されるようになり、より良い症状管理のための有望な結果が示されています。これは、より良い疾患管理、生活の質の向上、慢性副鼻腔炎に関連するヘルスケア負担の軽減につながります。

例えば、2021年7月29日、グラクソ・スミスクラインplc（GSK）は、米国食品医薬品局がインターロイキン-5（IL-5）を標的とするモノクローナル抗体であるヌカラ（メポリズマブ）を鼻ポリープを伴う慢性副鼻腔炎（CRSwNP）患者の治療薬として承認したと発表しました。このメポリズマブの新たな適応は、鼻副腎皮質ステロイドの効果が不十分な18歳以上の成人患者におけるCRSwNPの上乗せ維持療法です。

資金と投資の不足が市場成長の妨げになる

慢性副鼻腔炎に対する資金と投資の不足が、予測期間中の市場成長の妨げになると予想されます。慢性副鼻腔炎の原因、メカニズム、潜在的な治療法に関する調査活動を行うには、十分な資金が不可欠です。十分な資金がなければ、研究者は治験の実施、新たな治療法の開発、革新的な治療アプローチの探求などの課題に直面します。

さらに、慢性副鼻腔炎に対する新しい治療薬を開発することは、アンメットニーズに対応するために非常に重要であり、そのためには研究開発に多額の投資が必要です。資金や投資の不足は、時として医薬品開発や承認プロセスの遅れにつながり、ひいては患者にとってより効果的な新しい治療法の利用を制限することにもなりかねません。そのため、適切な資金調達と投資は非常に重要です。

厳しい治療費設定も市場成長の妨げに

厳しい治療費は、予測期間を通じて市場シェアの妨げになると予想されます。高い価格設定は、より良い治療や治癒可能な治療を求める多くの慢性副鼻腔炎患者、特に保険適用が限られている人々のアクセスを制限する可能性があります。この高額な治療費は、慢性副鼻腔炎を適切に管理する患者を手の届かない存在にしています。その結果、予測期間中の市場成長が阻害される可能性があります。

高い治療費は、新規治療薬の研究活動や治験の妨げにもなります。最初に治療を開始した患者であっても、高額な費用が治療アドヒアランスの低下につながる可能性があります。慢性副鼻腔炎とそれに関連するリスクの管理において最良の結果を得るためには、一貫した継続的な治療が必要な場合が多いため、これは最適な結果をもたらさない可能性があります。

目次

第1章 調査手法と調査範囲

第2章 定義と概要

第3章 エグゼクティブサマリー

第4章 市場力学

  • 影響要因
    • 促進要因
      • 治験の増加
      • 慢性副鼻腔炎とそれに関連する治療法に対する認識の高まり
      • 規制当局による承認の増加
    • 抑制要因
      • 資金不足と投資不足
      • 治療に対する厳しい価格設定
    • 機会
    • 影響分析

第5章 産業分析

  • ポーターのファイブフォース分析
  • サプライチェーン分析
  • 価格分析
  • 規制分析

第6章 COVID-19分析

第7章 疾患表現型別

  • 非好酸球性慢性副鼻腔炎
  • 好酸球性慢性副鼻腔炎
  • 感染性慢性副鼻腔炎
  • アレルギー性真菌性副鼻腔炎
  • その他

第8章 治療タイプ別

  • 医療機器
    • 鼻腔洗浄装置
      • スクイズボトル
      • シリンジ
      • ネティポット
      • その他
    • デリバリーシステム
    • 呼気ステロイド溶出ステント
  • 薬剤
    • ステロイド薬
    • 抗生物質
    • ロイコトリエン調節薬
    • 生物製剤
    • その他
  • 点鼻薬
  • ステロイド点鼻薬
  • 手術
    • 内視鏡下副鼻腔手術
    • 機能的内視鏡副鼻腔手術
    • 副鼻腔中隔形成術
    • その他
  • その他

第9章 流通チャネル別

  • 病院薬局
  • 小売薬局
  • オンライン薬局

第10章 エンドユーザー別

  • 病院
  • 専門クリニック
  • 外来手術センター
  • その他

第11章 地域別

  • 北米
    • 米国
    • カナダ
    • メキシコ
  • 欧州
    • ドイツ
    • 英国
    • フランス
    • イタリア
    • スペイン
    • その他欧州
  • 南米
    • ブラジル
    • アルゼンチン
    • その他南米
  • アジア太平洋
    • 中国
    • インド
    • 日本
    • オーストラリア
    • その他アジア太平洋
  • 中東・アフリカ

第12章 競合情勢

  • 競合シナリオ
  • 市況/シェア分析
  • M&A分析

第13章 企業プロファイル

  • Lyra Therapeutics
    • 企業概要
    • 製品ポートフォリオと説明
    • 財務概要
    • 主な動向
  • Novartis
  • Medtronic plc
  • GlaxoSmithKline plc
  • AstraZeneca
  • Sanofi
  • Dr. Reddy's Laboratories Ltd.
  • Stryker Corporation
  • Bayer AG
  • Smith & Nephew

第14章 付録

目次
Product Code: PH6740

Market Overview

Global Chronic Rhinosinusitis Market reached US$ 2.6 billion in 2022 and is expected to reach US$ 4.5 billion by 2030, growing with a CAGR of 7.3% during the forecast period 2023-2030.

The global chronic rhinosinusitis market experiencing significant growth in recent years with various factors influencing its dynamics such as increasing prevalence, rising clinical trials for better treatment, and others. Government investments in the development of better treatment options will continue to drive and boost the global chronic rhinosinusitis market. The global industry is placing increasing emphasis on sustainable practices to reduce its impact.

Moreover, there is no cure for chronic rhinosinusitis, but the disease can be managed by using different types of medical devices such as nasal irrigation devices and other medical devices, drugs like steroids pills, antibiotics, biologics, and other drugs, nasal steroid sprays, and nasal drops. In severe situations, surgery is considered for better management of associated symptoms. Nasal steroid sprays are most commonly used for better management and they are considered as safe.

Similarly, North America dominates the chronic rhinosinusitis market, capturing the largest market share owing to the region's favorable reimbursement policies, increasing prevalence, advanced and well-established healthcare infrastructure, and presence of major players.

Owing to the increasing prevalence of chronic rhinosinusitis, increasing awareness, rising clinical trials, increasing demand for novel therapeutics, increasing adoption of personalized medicines, rising demand for minimally invasive procedures, and advancements in treatment options are the major factors expected to drive the global chronic rhinosinusitis market over the forecast period.

Market Dynamics

Rising Clinical Trials are Expected to Drive the Growth of the Chronic Rhinosinusitis Market

The increasing number of clinical trials on chronic rhinosinusitis is expected to drive the market over the forecast period. Clinical trials are mainly performed to know the safety and efficacy of new drugs, medical devices, and other therapeutics and also provide valuable insights into the underlying mechanisms of chronic rhinosinusitis. The positive clinical trials encourage patients for using novel therapeutics.

For instance, For instance, on February 22, 2022, Biohaven Pharmaceutical Holding Company Ltd., a commercial-stage biopharmaceutical company with a portfolio of innovative, late-stage product candidates targeting neurological and neuropsychiatric diseases, announced that it has commenced enrollment in a Phase 2/3 clinical trial assessing the efficacy and safety of Nurtec ODT (rimegepant) 75 mg in patients with chronic rhinosinusitis (CRS) with or without nasal polyps.

Moreover, the positive trial results can also lead to the approval and introduction of novel treatment options by expanding the range of treatment choices available to patients for better and enhanced management of chronic rhinosinusitis. The clinical trials also engage the opportunities to perform research activities for more advanced treatments, which results in better management of the disease and improved patient outcomes.

For instance, on September 8, 2022, Lyra Therapeutics, Inc., a clinical-stage therapeutics company leveraging its proprietary XTreo platform to enable precise, sustained, and local delivery of medications to the ear, nose, and throat (ENT) passages and other diseased tissues, announced the enrollment of the first patient in the Phase 3 ENLIGHTEN II clinical trial of LYR-210 in adult patients with chronic rhinosinusitis (CRS). LYR-210 is designed as an alternative to sinus surgery for the millions of CRS patients that remain symptomatic despite treatment.

Increasing Awareness of Chronic Rhinosinusitis and Their Associated Treatments Expected to Drive the Growth of the Market

Increasing awareness of chronic rhinosinusitis and its associated treatments is expected to drive the market over the forecast period. The increased awareness can help individuals recognize the symptoms of chronic rhinosinusitis at an earlier stage. This can lead to quicker medical consultations, early diagnosis, and better management. The increasing awareness also improves care and better patient outcomes.

For instance, on April 20, 2023, EUFOREA announced the launch of its 2nd annual Chronic Rhinosinusitis with Nasal Polyps (CRSwNP) Awareness Day on April 20 2023 in Brussels, Belgium. The aims of this campaign include raising awareness of CRSwNP and comorbidities, encouraging healthcare professionals at all levels to provide specialist care, and educating patients on the symptoms of CRSwNP.

Moreover, many people with chronic rhinosinusitis may not realize they have the condition, attributing their symptoms to other factors. This increased awareness through awareness campaigns can help individuals to understand that their symptoms could be indicative of a medical condition, leading to proper diagnosis and treatment. The increased awareness also increases the demand for novel treatment options.

Increasing Regulatory Approvals Also Expected to Drive the Growth of the Chronic Rhinosinusitis Market

Increasing regulatory approvals drive the growth of the market over the forecast period by enabling the introduction of new treatment options for the management of chronic rhinosinusitis. This can further provide the patients with enhanced and better treatment options. The regulatory approvals increase the development of innovative treatment options by addressing the unmet needs associated with chronic rhinosinusitis treatment.

For instance, on May 04, 2023, Optinose, a pharmaceutical company focused on patients treated by ear, nose, and throat (ENT) and allergy specialists, announced the U.S. Food and Drug Administration (FDA) accepted for review its supplemental new drug application requesting approval of XHANCE as a treatment for chronic rhinosinusitis. XHANCE (fluticasone propionate) nasal spray is a drug-device combination product that combines the most widely used nasal anti-inflammatory drug with the innovative Exhalation Delivery System (EDS).

Additionally, regulatory approvals also allows the approved treatments to become accessible to a larger patient population, which shows promising results for the better management of the symptoms. This can lead to better disease management, improved quality of life, and reduced healthcare burdens which are associated with chronic rhinosinusitis.

For instance, on July 29, 2021, GlaxoSmithKline plc (GSK) announced that the US Food and Drug Administration has approved Nucala (mepolizumab), a monoclonal antibody that targets interleukin-5 (IL-5), as a treatment for patients with chronic rhinosinusitis with nasal polyps (CRSwNP). This new indication for mepolizumab is for the add-on maintenance treatment of CRSwNP in adult patients 18 years of age and older with inadequate response to nasal corticosteroids.

Lack of Funding and Investments Will Hamper the Market's Growth

The lack of funding and investments in chronic rhinosinusitis is expected to hamper the market growth over the forecast period. Adequate funding is crucial for conducting research activities into the causes, mechanisms, and potential treatments for chronic rhinosinusitis. Without sufficient funding, researchers face challenges to conduct clinical trials, developing new therapies, and exploring innovative treatment approaches.

Moreover, developing new medications for chronic rhinosinusitis is very crucial to address the unmet needs and that requires significant investment in research and development. The lack of funding and investments sometimes leads to delays in drug development and approval processes, which in turn can limit the availability of new and more effective treatments for patients. So proper funding and investments are very crucial.

Stringent Pricing of the Treatment Will Also Hampers the Market Growth

The stringent treatment costs are expected to hamper the market share over the forecast period. High pricing can limit access for many chronic rhinosinusitis patients who are seeking better and curable treatment, especially for people with limited insurance coverage. This high treatment cost makes patients unaffordable for proper management of chronic rhinosinusitis. This can results in the hampering the market growth over the forecast period.

The high treatment costs also hamper the research activities and clinical trials for novel therapeutics. Even among patients who initially start treatment, high costs may lead to reduced treatment adherence. This can result in suboptimal outcomes, as consistent and continuous treatment is often necessary for the best results in the management of chronic rhinosinusitis and its associated risks.

Segment Analysis

The global chronic rhinosinusitis market is segmented based on disease phenotype, treatment type, distribution channel, end-user and region.

The Steroid Nasal Sprays from the Treatment Type Segment Accounted for Approximately 45.3% of the Chronic Rhinosinusitis Market Share

Steroid nasal sprays hold the largest market share over the forecast period by playing a crucial role in the management of chronic rhinosinusitis. Steroid nasal sprays such as mometasone (also known as Nasonex) and fluticasone (Avamys or Flixonase) are very commonly used medications in the nasal sprays for chronic rhinosinusitis. Steroid nasal sprays are anti-inflammatory medications helps to suppress the immune response in chronic rhinosinusitis.

For instance, on May 3, 2023, Bausch Health Companies Inc. is pleased to announce the availability across Canada of its new prescription treatment RYALTRIS (olopatadine hydrochloride and mometasone furoate (medium-strength corticosteroid) nasal spray).

Moreover, steroid nasal sprays are primarily used in the management of chronic rhinosinusitis due to their promising results. Unlike oral corticosteroids, which can have significant systemic side effects when taken in higher doses or over a prolonged period, nasal sprays deliver the medication directly to the nasal passages with minimal side effects. This reduces the likelihood of systemic side effects and increases the adoption and wide acceptability.

Geographical Penetration

North America Accounted for Approximately 39.5% of the Market Share in 2022, Owing to the Increasing Prevalence and Strong Presence of Major Players

North America region is expected to hold the largest market share over the forecast period mainly owing to the increasing prevalence of chronic rhinosinusitis and the strong presence of major players in the region. There is a continuously increasing prevalence of chronic rhinosinusitis due to the largest population in the region. For instance, according to the NIH, chronic rhinosinusitis (CRS) is one of the most common chronic medical conditions worldwide, affecting all age groups. Its estimated incidence is 12.3% in the USA.

Moreover, in North America, especially in the United States and Canada, there is a strong presence of major players including pharmaceutical companies and research institutes that majorly focus on the development of novel therapeutics for the management of chronic rhinosinusitis. These major players are also actively performing the clinical trials and research activities.

For instance, on March 14, 2022, AstraZeneca announced that the US Food and Drug Administration (FDA) has issued a complete response letter (CRL) regarding the supplemental Biologics License Application (sBLA) for Fasenra (benralizumab) for patients with inadequately controlled chronic rhinosinusitis with nasal polyps (CRSwNP).

Competitive Landscape

The major global players in the chronic rhinosinusitis market include Lyra Therapeutics, Novartis, Medtronic plc, GlaxoSmithKline plc, AstraZeneca, Sanofi, Dr. Reddy's Laboratories Ltd., Stryker Corporation, Bayer AG, and Smith & Nephew among others.

COVID-19 Impact Analysis

The outbreak of the COVID-19 pandemic in late 2019 created unprecedented challenges for pharmaceutical industries worldwide, including the global chronic rhinosinusitis market. During the pandemic, many clinical trials, research activities, and regulatory approvals have been temporarily postponed due to the redirected focus towards the COVID-19 pandemic and its related restrictions.

The onset of the pandemic in early 2020 led to widespread lockdowns and restrictions, impacting regular check-ups, appointments, and consultations worldwide. Many hospitals are focused on the COVID-19 cases, which further reduced nasal related treatments including chronic rhinosinusitis treatment and management of the symptoms.

Moreover, the COVID-19 pandemic severely disrupted global supply chains, impacting the transportation of raw materials such as nasal sprays, nasal drops, and medical devices. Movement restrictions and border closures delayed shipments and caused drug transportation delays. Additionally, some countries faced shortages of drugs for treatment due to disruptions in their supply chain networks.

Overall, telecommunication is a major focussing part during the COVID-19, which positively impacted the market. This telecommunication allows patients with timely diagnoses and better treatment with reduced consultation costs and time. It is mainly useful for patients who are living in remote areas.

Russia-Ukraine Conflict Analysis

The Russia-Ukraine conflict is estimated to have a moderate impact on the global chronic rhinosinusitis market. Many clinical trials and research activities of chronic rhinosinusitis are temporarily disrupted due to conflict-related issues. The conflict has less impact mainly due to the low prevalence and absence of key market players in this region.

By Disease Phenotype

  • Non-Eosinophilic Chronic Rhinosinusitis
  • Eosinophilic Chronic Rhinosinusitis
  • Infectious Chronic Rhinosinusitis
  • Allergic Fungal Rhinosinusitis
  • Others

By Treatment Type

  • Medical Devices
  • Nasal Irrigation Devices

Squeeze Bottle Devices

Syringes

Neti Pots

Others

  • Exhalation Delivery Systems
  • Steroid-Eluting Stents
  • Drugs
  • Steroid Pills
  • Antibiotics
  • Leukotriene Modifiers
  • Biologics
  • Others
  • Nasal Drops
  • Steroid Nasal Sprays
  • Surgery
  • Endoscopic Sinus Surgery
  • Functional Endoscopic Sinus Surgery
  • Sinus Septoplasty
  • Others
  • Others

By Distribution Channel

  • Hospital Pharmacies
  • Retail Pharmacies
  • Online Pharmacies

By End-User

  • Hospitals
  • Specialty Clinics
  • Ambulatory Surgical Centers
  • Others

By Region

  • North America

U.S.

Canada

Mexico

  • Europe

Germany

U.K.

France

Spain

Italy

Rest of Europe

  • South America

Brazil

Argentina

Rest of South America

  • Asia-Pacific

China

India

Japan

Australia

Rest of Asia-Pacific

  • Middle East and Africa

Key Developments

  • On June 02, 2023, Lyra Therapeutics, Inc., a clinical-stage biotechnology company developing innovative therapies for the localized treatment of chronic rhinosinusitis (CRS), announced that it has issued an equity-based award pursuant to its 2022 Inducement Award Plan to its Senior Vice President of Regulatory Affairs, Allison Nance, upon the commencement of her employment. The inducement grant consists of a non-qualified stock option to purchase an aggregate of 110,000 shares of the Company's common stock.
  • On February 9, 2023, H2Ocean LLC published a clinical study on the efficacy of their sea salt-based nasal spray, Nasalzyme, which can relieve the symptoms of chronic rhinosinusitis. H2Ocean's Nasalzyme, a non-addictive nasal spray made of all-natural ingredients, including unrefined sea salt harvested from the Red Sea, and naturally occurring enzymes contains key components that act to relieve chronic rhinosinusitis and other sinus conditions.
  • On October 14, 2022, Bio-Thera Solutions, Ltd., a commercial-stage biopharmaceutical company, announced that dosing has begun in Phase I clinical study to compare the pharmacokinetics and safety of BAT2606, a proposed biosimilar of Nucala (mepolizumab), to US-sourced and EU-sourced reference product in normal healthy volunteers. The clinical study is a randomized, double-blind, parallel-group, single-dose study that is expected to enroll approximately 207 healthy volunteers.

DataM Intelligence Opinion:

According to the DataM Intelligence, the chronic rhinosinusitis market experiencing the rapid growth in recent years and is expected to grow rapidly in the coming years due to its increasing prevalence and as there is no cure for this disease but, novel therapeutic innovations are developing for better patient outcomes. Many innovative treatment options are going to develop in the coming years by reducing the adverse effects and for effective treatment. Moreover, many clinical trials and research activities are still going on for novel therapeutics, which is expected to growth of the global chronic rhinosinusitis market in the upcoming years.

Why Purchase the Report?

  • To visualize the global chronic rhinosinusitis market segmentation based on disease phenotype, treatment type, distribution channel, end-user, and region as well as understand key commercial assets and players.
  • Identify commercial opportunities by analyzing trends and co-development.
  • Excel data sheet with numerous data points of chronic rhinosinusitis market-level with all segments.
  • PDF report consists of a comprehensive analysis after exhaustive qualitative interviews and an in-depth study.
  • Product mapping available as excel consisting of key products of all the major players.

The global chronic rhinosinusitis market report would provide approximately 61 tables, 58 figures, and 186 Pages.

Target Audience 2023

  • Manufacturers/ Buyers
  • Industry Investors/Investment Bankers
  • Research Professionals
  • Emerging Companies

Table of Contents

1. Methodology and Scope

  • 1.1. Research Methodology
  • 1.2. Research Objective and Scope of the Report

2. Definition and Overview

3. Executive Summary

  • 3.1. Snippet by Disease Phenotype
  • 3.2. Snippet by Treatment Type
  • 3.3. Snippet by Distribution Channel
  • 3.4. Snippet by End-User
  • 3.5. Snippet by Region

4. Dynamics

  • 4.1. Impacting Factors
    • 4.1.1. Drivers
      • 4.1.1.1. Rising Clinical Trials
      • 4.1.1.2. Increasing Awareness of Chronic Rhinosinusitis and Their Associated Treatment Options
      • 4.1.1.3. Increasing Regulatory Approvals
    • 4.1.2. Restraints
      • 4.1.2.1. Lack of Funding and Investments
      • 4.1.2.2. Stringent Pricing for the Treatment
    • 4.1.3. Opportunity
    • 4.1.4. Impact Analysis

5. Industry Analysis

  • 5.1. Porter's Five Force Analysis
  • 5.2. Supply Chain Analysis
  • 5.3. Pricing Analysis
  • 5.4. Regulatory Analysis

6. COVID-19 Analysis

  • 6.1. Analysis of COVID-19
    • 6.1.1. Scenario Before COVID
    • 6.1.2. Scenario During COVID
    • 6.1.3. Scenario Post COVID
  • 6.2. Pricing Dynamics Amid COVID-19
  • 6.3. Demand-Supply Spectrum
  • 6.4. Government Initiatives Related to the Market During the Pandemic
  • 6.5. Manufacturers Strategic Initiatives
  • 6.6. Conclusion

7. By Disease Phenotype

  • 7.1. Introduction
    • 7.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Disease Phenotype
    • 7.1.2. Market Attractiveness Index, By Disease Phenotype
  • 7.2. Non-Eosinophilic Chronic Rhinosinusitis *
    • 7.2.1. Introduction
    • 7.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
  • 7.3. Eosinophilic Chronic Rhinosinusitis
  • 7.4. Infectious Chronic Rhinosinusitis
  • 7.5. Allergic Fungal Rhinosinusitis
  • 7.6. Others

8. By Treatment Type

  • 8.1. Introduction
    • 8.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Treatment Type
    • 8.1.2. Market Attractiveness Index, By Treatment Type
  • 8.2. Medical Devices *
    • 8.2.1. Introduction
    • 8.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
    • 8.2.3. Nasal Irrigation Devices
      • 8.2.3.1. Squeeze Bottle Devices
      • 8.2.3.2. Syringes
      • 8.2.3.3. Neti Pots
      • 8.2.3.4. Others
    • 8.2.4. Delivery Systems
    • 8.2.5. Exhalation Steroid-Eluting Stents
  • 8.3. Drugs
    • 8.3.1. Steroid Pills
    • 8.3.2. Antibiotics
    • 8.3.3. Leukotriene Modifiers
    • 8.3.4. Biologics
    • 8.3.5. Others
  • 8.4. Nasal Drops
  • 8.5. Steroid Nasal Sprays
  • 8.6. Surgery
    • 8.6.1. Endoscopic Sinus Surgery
    • 8.6.2. Functional Endoscopic Sinus Surgery
    • 8.6.3. Sinus Septoplasty
    • 8.6.4. Others
  • 8.7. Others

9. By Distribution Channel

  • 9.1. Introduction
    • 9.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
    • 9.1.2. Market Attractiveness Index, By Distribution Channel
  • 9.2. Hospital Pharmacies *
    • 9.2.1. Introduction
    • 9.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
  • 9.3. Retail Pharmacies
  • 9.4. Online Pharmacies

10. By End-User

  • 10.1. Introduction
    • 10.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
    • 10.1.2. Market Attractiveness Index, By End-User
  • 10.2. Hospitals *
    • 10.2.1. Introduction
    • 10.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
  • 10.3. Specialty Clinics
  • 10.4. Ambulatory Surgical Centers
  • 10.5. Others

11. By Region

  • 11.1. Introduction
    • 11.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Region
    • 11.1.2. Market Attractiveness Index, By Region
  • 11.2. North America
    • 11.2.1. Introduction
    • 11.2.2. Key Region-Specific Dynamics
    • 11.2.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Disease Phenotype
    • 11.2.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Treatment Type
    • 11.2.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
    • 11.2.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
    • 11.2.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
      • 11.2.7.1. U.S.
      • 11.2.7.2. Canada
      • 11.2.7.3. Mexico
  • 11.3. Europe
    • 11.3.1. Introduction
    • 11.3.2. Key Region-Specific Dynamics
    • 11.3.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Disease Phenotype
    • 11.3.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Treatment Type
    • 11.3.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
    • 11.3.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
    • 11.3.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
      • 11.3.7.1. Germany
      • 11.3.7.2. UK
      • 11.3.7.3. France
      • 11.3.7.4. Italy
      • 11.3.7.5. Spain
      • 11.3.7.6. Rest of Europe
  • 11.4. South America
    • 11.4.1. Introduction
    • 11.4.2. Key Region-Specific Dynamics
    • 11.4.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Disease Phenotype
    • 11.4.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Treatment Type
    • 11.4.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
    • 11.4.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
    • 11.4.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
      • 11.4.7.1. Brazil
      • 11.4.7.2. Argentina
      • 11.4.7.3. Rest of South America
  • 11.5. Asia-Pacific
    • 11.5.1. Introduction
    • 11.5.2. Key Region-Specific Dynamics
    • 11.5.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Disease Phenotype
    • 11.5.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Treatment Type
    • 11.5.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
    • 11.5.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
    • 11.5.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
      • 11.5.7.1. China
      • 11.5.7.2. India
      • 11.5.7.3. Japan
      • 11.5.7.4. Australia
      • 11.5.7.5. Rest of Asia-Pacific
  • 11.6. Middle East and Africa
    • 11.6.1. Introduction
    • 11.6.2. Key Region-Specific Dynamics
    • 11.6.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Disease Phenotype
    • 11.6.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Treatment Type
    • 11.6.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
    • 11.6.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User

12. Competitive Landscape

  • 12.1. Competitive Scenario
  • 12.2. Market Positioning/Share Analysis
  • 12.3. Mergers and Acquisitions Analysis

13. Company Profiles

  • 13.1. Lyra Therapeutics *
    • 13.1.1. Company Overview
    • 13.1.2. Product Portfolio and Description
    • 13.1.3. Financial Overview
    • 13.1.4. Key Developments
  • 13.2. Novartis
  • 13.3. Medtronic plc
  • 13.4. GlaxoSmithKline plc
  • 13.5. AstraZeneca
  • 13.6. Sanofi
  • 13.7. Dr. Reddy's Laboratories Ltd.
  • 13.8. Stryker Corporation
  • 13.9. Bayer AG
  • 13.10. Smith & Nephew

LIST NOT EXHAUSTIVE

14. Appendix

  • 14.1. About Us and Services
  • 14.2. Contact Us